Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of oral ceritinib versus standard chemotherapy in previously treated ALK-positive advanced NSCLC
jRCT2080222222Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ceritinib in ALK-positive non-small cell lung cancer (2 arms), sponsored by Novartis. Started Sep 2013; status: completed.
02
Drugs
ceritinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on jRCT2080222222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222222.